| # | Drug | Count |
|---|---|---|
| 0 | TRASTUZUMAB | 1605 |
| 1 | CAPECITABINE | 1082 |
| 2 | CARBOPLATIN | 810 |
| 3 | PACLITAXEL | 754 |
| 4 | DEXAMETHASONE | 671 |
| 5 | OSIMERTINIB | 671 |
| 6 | DEXAMETHASONE 1.5 MG | 670 |
| 7 | PERTUZUMAB | 670 |
| 8 | PACLITAXEL (AIBUMIN-BOUND) | 668 |
| 9 | BEVACIZUMAB | 613 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | CERITINIB | 172 | 0.0721 |
| 1 | BRIGATINIB | 242 | 0.0662 |
| 2 | ADO-TRASTUZUMAB EMTANSINE | 409 | 0.0484 |
| 3 | GEFITINIB | 377 | 0.0419 |
| 4 | AFATINIB | 270 | 0.0408 |
| 5 | LAPATINIB | 486 | 0.0315 |
| 6 | ENTRECTINIB | 46 | 0.0272 |
| 7 | FAM-TRASTUZUMAB DERUXTECAN-NXKI | 279 | 0.0256 |
| 8 | VINORELBINE | 173 | 0.0248 |
| 9 | PERTUZUMAB | 670 | 0.0243 |
| # | Drug class | Count |
|---|---|---|
| 0 | Kinase Inhibitor [EPC] | 3095 |
| 1 | HER2/neu Receptor Antagonist [EPC] | 1705 |
| 2 | Platinum-based Drug [EPC] | 1268 |
| 3 | Nucleoside Metabolic Inhibitor [EPC] | 1264 |
| 4 | Microtubule Inhibitor [EPC] | 1196 |
| 5 | Corticosteroid [EPC] | 1181 |
| 6 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 1102 |
| 7 | Aromatase Inhibitor [EPC] | 665 |
| 8 | Nonsteroidal Anti-inflammatory Drug [EPC] | 647 |
| 9 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 642 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-5 Antagonist [EPC] | 26 | 0.0378 |
| 1 | Endoglycosidase [EPC] | 63 | 0.0340 |
| 2 | HER2/neu Receptor Antagonist [EPC] | 1705 | 0.0228 |
| 3 | Programmed Death Ligand-1 Blocker [EPC] | 376 | 0.0174 |
| 4 | Bispecific HER2-directed Antibody [EPC] | 1 | 0.0122 |
| 5 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 1102 | 0.0112 |
| 6 | Estrogen Receptor Antagonist [EPC] | 405 | 0.0100 |
| 7 | Lymphocyte Growth Factor [EPC] | 12 | 0.0095 |
| 8 | Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC] | 5 | 0.0083 |
| 9 | Protease Activator [EPC] | 1 | 0.0078 |